- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA ...
ANDEMBRY® is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in HAE patients. The approval marks the fifth regulatory approval of ANDEMBRY, reinforcing CSL ...
Featuring releases from CSL, CSL Behring, CSL Seqirus and CSL Vifor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback